期刊文献+

同步化放疗结合清肺八味汤治疗局部晚期非小细胞肺癌的临床研究 被引量:5

Clinical Observation of Qingfei Bawei Decoction Combined with Concurrent Chemoradiotherapy in Non-small Cell Lung Cancer
原文传递
导出
摘要 目的:探讨同步化放疗结合清肺八味汤治疗局部晚期非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)患者的临床疗效。方法:53例接受治疗的患者,随机分入联合组,同步化放疗结合清肺八味汤治疗和对照组仅同步化放疗,评定疗效和不良反应。结果:联合组疗效及KPS评分优于对照组,中性粒细胞减少少于对照组,差异有统计学意义(P<0.05)。结论:同步化放疗结合清肺八味汤能有效减轻局部晚期非小细胞肺癌化放疗的不良反应,提高疗效和生存质量。 Objective:To explore the clinical outcome of Qingfei Bawei Decoction combined with concurrent chemoradiotherapy in patients with non - small cell lung cancer (NSCLC). Methods : Fifty - three inpatients with NSCLC were randomly divided into Qingfei Bawei Decoction group which was treated with Qingfei Bawei Decoction combined with concurrent chemoradiotherapy and control group which was treated with single concurrent chemoradiotherapy. The responses and toxicities were compared between the two groups. Results : In the short - term response it showed that Qingfei Bawei Decoction group responded better than control group( P 〈 0.05 ). The performance status of Qingfei Bawei Decoction group, according to KPS questionaire,was higher than that of control group (P 〈 0.05). As to the neutropenia, Qingfei Bawei Decoction group suffered less than control group(P 〈 0. 05). Conclusion:Qingfei Bawei Decoction combined with concurrent chemoradiotherapy can enhance clinical therapeutic effect, improve the quality of life and reduce the toxicities of patients with locally advanced NSCLC.
机构地区 浙江省人民医院
出处 《中华中医药学刊》 CAS 2013年第6期1275-1277,共3页 Chinese Archives of Traditional Chinese Medicine
基金 国家中医药管理局资助项目(201209) 浙江省中医药管理局资助项目(2010ZR001)
关键词 非小细胞肺癌 化放疗 清肺八味汤 non - small cell lung cancer chemoradiotherapy Qingfei Bawei Decoction
  • 相关文献

参考文献6

二级参考文献22

共引文献65

同被引文献63

  • 1唐黎群,潘智敏.潘智敏清肺八味汤解析[J].中医药学刊,2006,24(11):1992-1993. 被引量:1
  • 2仇晓军,马剑波,季斌,赵洪瑜.康莱特加同步放化疗治疗局部晚期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):131-133. 被引量:14
  • 3王建中,张长春.康莱特胶丸加同步放化疗治疗局部晚期非小细胞肺癌的临床研究[J].中华肿瘤防治杂志,2007,14(19):1502-1503. 被引量:6
  • 4卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:354.
  • 5NCCN. The NCCN non - small lung cancer clinical practice guidelines in oneology (version 1.2013) . [2014 - 05 - 06] .http: // www. necn. org/professionals/physieian_ gls/f_ guidelines, asp.
  • 6Hirata K, Takayama K, Kawaguchi T, et al. Discussion. Meeting on the diagnosis and treatment of lung cancer [ J ]. Nihon Naika Gakkai Zasshi, 2014, 103 (6) : 1360-1374.
  • 7Xie CY,Xu YP,Jin W,et al.Antitumor activity of lobaplatin alone or in combination with antitubulin agents in nonsmall-cell lung cancer[J].Anticancer Drugs,2012,23(7):698.
  • 8Tsoutsou P G,Koukourakis M I.Radiation pneumonitis and fibrosis:Mechanisms underlying its pathogenesis and implications for future research[J].Int J Radiat Oncol Biol Phys,2006,66(5):1281-1293.
  • 9Cox JD,Stetz J,Pajak TF.Toxicity criteria of the Radiation Therapy Oncology Group(RTOG)and the European Organization for Research and Treatment of Cancer(EORTC)[J].Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346.
  • 10Palma DA,Senan S,Tsujino K,et al.Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.

引证文献5

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部